Scrip
New products and stem cell deal hold out promise for MS
26 January 2010
Ian Schofield
Please Login to read the full article.
26 January 2010
Ian Schofield
The recent US approval of Ampyra, US and EU filings for fingolimod and the announcement of a UK collaboration on stem cell research are welcome developments for multiple sclerosis patients and doctors awaiting potential new treatments for this intractable and distressing disease.
MS is the...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Merck Serono's cladribine may become first oral MS drug after positive Phase III results
- Novartis files oral MS drug fingolimod in US and EU
- No clear path forward for secondary-progressive MS, says BioMS
- Novartis reports positive data for second fingolimod Phase III study in MS - update
FEATURES
- Anti-obesity drugs: an inventor's perspective
- Roche's Asian partnering head looks to tap regional innovation
EVENTS
22 March 2010
London, UK
12 April 2010
Orlando, Florida
13 April 2010
London, UK
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
